Marizyme acquired DuraGraft through the 2019 purchase of Somahlution assets.
Duragraft is designed for tissue preservation
Krillase®, a previously patented protease-based therapeutic, is a naturally occurring enzyme extract that acts to break protein bonds and has potential applications in dental care, wound healing and thrombolysis.
Acquired by Marizyme from Swedish company ACB Holding AB, Krillase received medical device status in the European Union for debridement of deep partial and full-thickness wounds in hospitalized patients on July 19, 2005. Marizyme is currently investigating if a medical device status is still accepted as the Medical Device Directive was updated in 2007 and the new Medical Device Regulation becomes effective in 2021. Krillase is not yet approved for use in the EU or U.S.
Krillase activity is unique – it is the only enzymatic product based on a co-operative multi-enzyme system involving both endo- and exopeptidases.
The proteolytic enzymes of Krillase are composed of eight natural enzymes acting in a synergetic manner, including:
Krill enzymes are also unique in that they are mutually protected against the degrading effect of each other and they act in a two-step fashion when breaking down proteinaceous substrates.
Marizyme currently has four product candidates derived from Krillase.